Translational Neuroscience Optimization of GlyT1 Inhibitor

Conditions

Schizophrenia

What is the purpose of this trial?

This study involves an interlinked design to determine the dose associated with optimal activity and occupancy of the Glyt1I PF-03463275 in healthy subjects and schizophrenia subjects and to test this dose in combination with cognitive remediation in the treatment of cognitive impairments of Schizophrenia.


Participation Guidelines

Age:
21 Years - 55 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Institutes of Health
Dates:
07/18/2013
Last Updated:
Study HIC#:
1303011716